Teva, Bezeq and Azrieli led the gains on the market today as Tower fell on disappointing results.
Analyst Chris Schott has upgraded Teva from "Underweight" to "Neutral" but maintained the $8 price target, a 16.4% downside on the current share price.
Source: gopixa / iStockStocks were mixed in the premarket on Tuesday and the day was just looking for direction after last week’s all-time highs. Investors still have a lot of...
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported third-quarter 2019 earnings of 58 cents per share, which missed the Zacks Consensus Estimate of 60 cents. Earnings per...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Strong Buy||Strong Buy||Buy||Sell|
|Technical Indicators||Strong Buy||BUY||Strong Buy||Strong Buy||Strong Sell|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Belt Hold Bearish||5H||Current|
|Bullish doji Star||1M||2||Sep 19|
|Three Outside Up||1W||3||Oct 20, 2019|
|Deliberation Bearish||5H||3||Nov 12, 2019 05:00PM|
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.